Evidence map›Paper›PMID 39144905›Full record

ArticleCureus2024

Evaluation of Hemoglobin and Eosinophil Count in Patients Receiving Thrombolytic Treatment.

Ramiz Yazıcı, Muhammed Güner, Ayşe F Basa Kalafat, Rabia B Tapkan, Hilmi Kaya, Bilal Yeniyurt, Salih Fettahoğlu, Utku M Kalafat, Efe D Bala, Serkan Doğan

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ramiz YazıcıEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Muhammed GünerEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Ayşe F Basa KalafatEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Rabia B TapkanEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Hilmi KayaEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Bilal YeniyurtEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Salih FettahoğluEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Utku M KalafatEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Efe D BalaEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.
Serkan DoğanEmergency Medicine, İstanbul Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, İstanbul, TUR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim Stroke ranks among the primary contributors to disability and mortality on a global scale. Recent advances in ischemic stroke pathophysiology emphasize the significant role of the immune system in both stroke-related damage and neuroprotection. This article investigates the relationship between hemoglobin level and white blood cell count. Materials and methods From January 1, 2019, to April 1, 2022, all patients aged 18 years and over who were diagnosed with acute ischemic stroke in the emergency department of Kanuni Sultan Süleyman Training and Research Hospital and treated with intravenous recombinant tissue plasminogen activator (r-tPA) within 4.5 hours of stroke onset were included in this cross-sectional retrospective study. Gender, age, onset of symptoms, complaints, National Institutes of Health Stroke Scale (NIHSS) score, stroke-affected area, as well as leukocyte, neutrophil, platelet, eosinophil, lymphocyte, and hemoglobin levels were recorded and compared between mortality and survivor groups. Results A total of 61 people, including 33 men and 28 women, were included in the study. Four patients died during follow-ups. The mean duration of symptoms upon admission was 86.23 ± 56.37 minutes. The mean NIHSS score of patients was found to be 9.16 ± 3.88 (minimum: 4, maximum: 18). There was a statistically significant positive correlation between age and symptom duration (p < 0.002, r: 0.391). A statistically significant negative correlation was found between eosinophil count and NIHSS score (p < 0.012, r: -0.321) and between eosinophil count and symptom duration (p < 0.042, r: -0.261). There was a negative correlation between hemoglobin levels and mortality (p < 0.013, r: -0.318). A statistically significant negative correlation was observed between the eosinophil-to-neutrophil ratio (ENR) and NIHSS score (p < 0.017, r: -0.305) as well as between ENR and symptom duration (p < 0.034, r: -0.271). Hemoglobin is a significant predictor of mortality in the logistic regression model (p < 0.05, CI: 0.253-0.942). For each one-unit increase in hemoglobin, the odds of mortality decrease by a factor of 0.488. Conclusion Certain blood cell types (neutrophils, eosinophils, and lymphocytes) play an active role in determining stroke prognosis. A detailed explanation of the role of leukocyte types lays the foundation for "immunomodulation," which could be a promising novel treatment modality for future stroke patients.

Indexed as

eosinophilhemoglobinimmunomodulationischemic strokethrombolytic

Identifiers

PMID39144905
PMCPMC11323790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.